Expert Review of Vaccines最新文献_第2页

Adherence and efficacy of the 0 - 7 - 21-day versus the 0 - 1 - 6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial. 在使用药物的人群中，0 - 7 - 21天与0 - 1- 6个月乙肝疫苗接种计划的依从性和有效性：一项为期两年的随机对照试验

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-08 DOI: 10.1080/14760584.2026.2626920

Xianbin Hou, Ning Li, Hailan Zhang, Wenjun Liu, Haichao Zheng, Tianyi Zhuang, Zhuoru Zou, Ruyi Xia, Ying Liu, Hongyan Zhang, Tiejun Hou, Zhijun Chen, Baozhong Chen, Fuzhen Wang, Lirong Wang, Xiaoli Wei, Guihua Zhuang

{"title":"Adherence and efficacy of the 0 - 7 - 21-day versus the 0 - 1 - 6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial.","authors":"Xianbin Hou, Ning Li, Hailan Zhang, Wenjun Liu, Haichao Zheng, Tianyi Zhuang, Zhuoru Zou, Ruyi Xia, Ying Liu, Hongyan Zhang, Tiejun Hou, Zhijun Chen, Baozhong Chen, Fuzhen Wang, Lirong Wang, Xiaoli Wei, Guihua Zhuang","doi":"10.1080/14760584.2026.2626920","DOIUrl":"10.1080/14760584.2026.2626920","url":null,"abstract":"Background: To compare the adherence and efficacy between the 0 - 7 - 21-day and the 0 - 1 - 6-month hepatitis B virus (HBV) vaccination schedules among people who use drugs (PWUD) in China.Research design and methods: A randomized controlled trial was conducted in 1261 HBV-susceptible PWUD from compulsory isolated detoxification centers (CIDCs) and methadone maintenance treatment (MMT) clinics in Xi'an. A 20 µg per-dose vaccine was used. HBV surface antibody (anti-HBs), surface antigen, and core antibody were tested at months 7, 15, and 22 after the first dose.Results: Third-dose coverage was significantly higher in the 0 - 7 - 21-day group (74.40%) than in the 0 - 1 - 6-month group (51.58%, p < 0.001), mainly driven by participants from CIDCs (77.75% vs. 45.69%). Anti-HBs positive rates at months 7, 15, and 22 among participants who completed all three doses were significantly higher for the 0 - 1 - 6-month schedule (90.71%, 76.82%, and 67.35%) than for the 0 - 7 - 21-day schedule (74.23%, 49.40%, and 40.95%; all p < 0.001). HBV infection incidence was similar between schedules, but significantly different between vaccinees and non-vaccinees (p = 0.018).Conclusions: The 0 - 7 - 21-day schedule substantially enhances three-dose completion in PWUD, but induces a notably weaker anti-HBs response and persistence. Schedules should be selected based on the management models for PWUD and their individual characteristics.Clinical trial registration: Chinese Clinical Trial Registry (ChiCTR1900022403).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626920"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China. 中国带状疱疹减毒活疫苗安全性的自我对照病例系列研究。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-07 DOI: 10.1080/14760584.2026.2626926

Xiang Cao, Mingwei Wei, Xiang Huo, Yuanbao Liu, Ming Xu, Xiaoshan Wang, Xianzhang Huang, Hui Ma, Na Xu, Qiang Lu, Shihua Ma, Pengfei Jin, Jingxin Li

{"title":"A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China.","authors":"Xiang Cao, Mingwei Wei, Xiang Huo, Yuanbao Liu, Ming Xu, Xiaoshan Wang, Xianzhang Huang, Hui Ma, Na Xu, Qiang Lu, Shihua Ma, Pengfei Jin, Jingxin Li","doi":"10.1080/14760584.2026.2626926","DOIUrl":"10.1080/14760584.2026.2626926","url":null,"abstract":"Background: Herpes zoster (HZ), caused by varicella-zoster virus, primarily affects the elderly. In May 2023, the first domestically produced live attenuated zoster vaccine was approved for use in adults aged 40 years or older in China.Research design and methods: We conducted a self-controlled case series study to collect hospitalization events among 25,000 vaccinated adults (April 2020-December 2023, 5 regions) during the risk period (0-42 days) and the control period (72-162 days). Conditional Poisson regression models and conditional logistic regression models were applied to compare the risk of hospitalization.Results: The rate ratio of hospitalization following immunization was 0·381 (0·323-0·450). Compared with those in control period, the incidence rates of the following hospitalization events decreased: RRs of 0·297 (0·203-0·435) for stroke, cerebrovascular, and nervous system diseases; 0·296 (0·205-0·527) for cardiovascular diseases; 0·183 (0·054-0·627) for genitourinary system diseases; 0·246 (0·155-0·391) for respiratory, thoracic, and mediastinal diseases; 0·238 (0·089-0·635) for diseases of eye and adnexal diseases; and 0·202 (0·053-0·766) for skin and subcutaneous tissue diseases.Conclusions: This study confirms the safety of the live attenuated zoster vaccine, demonstrating that vaccination does not increase the risk of hospitalization and may even reduce the incidence of hospitalization.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626926"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global status of HPV vaccination two decades in: effective, safe and preventing cancer. 二十年来HPV疫苗接种的全球现状：有效、安全和预防癌症。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2025-12-30 DOI: 10.1080/14760584.2025.2609869

Julia M L Brotherton, D Scott LaMontagne, Paul J N Bloem

{"title":"Global status of HPV vaccination two decades in: effective, safe and preventing cancer.","authors":"Julia M L Brotherton, D Scott LaMontagne, Paul J N Bloem","doi":"10.1080/14760584.2025.2609869","DOIUrl":"10.1080/14760584.2025.2609869","url":null,"abstract":"Introduction: Prophylactic human papillomavirus vaccines have been in use in populations worldwide for nearly 20 years. Much has been learnt in relation to their effectiveness, safety, and how best to effectively implement them in populations to prevent cancer and other HPV-related diseases. Global challenges such as limited supply and the mismatch between those who can afford them and those with the greatest disease burden from cervical cancer have prevented optimal usage to date.Areas covered: Here we identified recent papers and focus upon the accumulated evidence regarding HPV vaccine: i) effectiveness in preventing cancer and precancerous lesions, ii) safety in population usage, iii) trial evidence supporting registration of four newer vaccines, iv) progress in country-level introductions and coverage, and v) lessons learned in effective implementation.Expert opinion: Reasons for optimism are many, with vast cumulative knowledge on impact, safety and implementation and accelerating HPV vaccine introductions, simplification of delivery and reduced costs through single dose approaches and supply constraints easing. However, considerable challenges remain in achieving and maintaining high and equitable global coverage, given the uncertainty in funding, risk to ongoing prioritization of health equity and to vaccine confidence in the current global public health environment.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2609869"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study. 肺炎球菌疫苗接种对患有炎症性肠病的儿童和青少年疾病活动性的影响：一项为期2年的前瞻性研究

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-30 DOI: 10.1080/14760584.2026.2652921

Magdalena Neścioruk, Kinga Kowalska-Duplaga, Urszula Grzybowska-Chlebowczyk, Agnieszka Sieczkowska, Aleksandra Banaszkiewicz

{"title":"The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study.","authors":"Magdalena Neścioruk, Kinga Kowalska-Duplaga, Urszula Grzybowska-Chlebowczyk, Agnieszka Sieczkowska, Aleksandra Banaszkiewicz","doi":"10.1080/14760584.2026.2652921","DOIUrl":"10.1080/14760584.2026.2652921","url":null,"abstract":"Background: Infectious diseases are known triggers for inflammatory bowel disease (IBD) exacerbations. Although vaccines can prevent many such infections, hesitancy persists among pediatric IBD patients and their caregivers due to concerns about vaccine-induced disease flare-ups. The aim of the study was to evaluate the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on disease activity in children and adolescents with IBD over a 24-month period post-vaccination.Research design and methods: This prospective, multicenter cohort study included IBD patients aged 4-18 years. Participants were assigned to a vaccinated group (single PCV13 dose) or an unvaccinated control group. Disease activity was monitored using PUCAI/PCDAI scores, and exacerbation rates were recorded at 6, 12, 18, and 24 months.Results: A total of 279 patients (52.3% male; median age, 167 months) were enrolled, of whom 93 (33.3%) received PCV13. The control group showed higher, but not statistically significant, disease activity at any time point (p = 0.06, 0.10, 0.64, 0.36) and exacerbation rates (p = 0.47, 0.17, 0.82, 0.75).Conclusion: A single dose of PCV13 does not increase disease activity in pediatric IBD patients during the 24 months following vaccination.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2652921"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development. 呼吸道病毒的新型疫苗平台：已获许可的疫苗和处于后期开发阶段的候选疫苗综述

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-05 DOI: 10.1080/14760584.2026.2667742

Sabiha R Hussain, Hana M El Sahly

{"title":"Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development.","authors":"Sabiha R Hussain, Hana M El Sahly","doi":"10.1080/14760584.2026.2667742","DOIUrl":"https://doi.org/10.1080/14760584.2026.2667742","url":null,"abstract":"Introduction: Respiratory infections with influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 are a major cause of global mortality. Vaccination is a cornerstone of disease prevention, though traditional platforms face challenges. Recently, several vaccines utilizing mRNA and adenovirus platforms were brought to the market, with additional vaccines undergoing Phase 3 clinical testing.Areas covered: This review assesses vaccine literature primarily from 2020 to the present, using National Library of Medicine databases. The rapidity of mRNA technology was tested and implemented successfully during the COVID-19 pandemic. Since then, the mRNA RSV vaccine has been licensed as well. mRNA platforms also offer the ability of combining antigens for multivalent vaccines against multiple pathogens. Several combination products have been used in phase III clinical trials. Adenovirus-vectored vaccines for respiratory viruses have the added advantage of mucosal-based delivery and inducing a potentially stronger local immune response. However, both of these platforms have immunogenicity and safety shortcomings.Expert opinion: Novel respiratory virus vaccine platforms have demonstrated their importance with both endemic and pandemic pathogens, because of decades of concerted efforts and investment in research. Expediting future vaccine development requires a continuation of these efforts with a focus on pre-clinical models and a better understanding of correlates of protection.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2667742"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica. 对哥斯达黎加使用COVID-19疫苗的疫苗接种战略的潜在公共卫生和经济影响以及成本效益进行建模。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-26 DOI: 10.1080/14760584.2026.2634800

Juan José Baldi-Castro, Carlos Fernando Mendoza, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Ben Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada

{"title":"Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica.","authors":"Juan José Baldi-Castro, Carlos Fernando Mendoza, Moe H Kyaw, Iustina Chirila, Leo Alejandro Barrantes, Elena Aruffo, Ben Yarnoff, Karen Villamil-Herrera, Marcel Marcano-Lozada","doi":"10.1080/14760584.2026.2634800","DOIUrl":"10.1080/14760584.2026.2634800","url":null,"abstract":"Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants.Research design and methods: Using a previously published, combined Markov-decision tree model adapted for Costa Rica, this study estimated the outcomes of different vaccination strategies with BNT162b2 COVID-19 mRNA vaccine, targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality-of-life inputs derived from the published literature and national surveillance data. Scenario analyses that implemented variation in COVID-19 incidence and sensitivity analyses were both conducted to assess uncertainty.Results: Compared to no adapted vaccine, the vaccination strategy in older adults aged ≥65 years and the high-risk population aged 18-64 years was estimated to prevent 3704 symptomatic cases, 3670 outpatient cases, 35 hospitalizations, 102 lost quality-adjusted life-years (QALYs), and one death, translating to total direct and societal cost savings of US$9,465,324 and US$10,569,883, respectively. Expanding vaccination to adults aged ≥60 years and high-risk individuals aged 18-59 years further increased benefits.Conclusions: Implementing an adapted COVID-19 vaccine strategy for high-risk and older adults in Costa Rica is expected to be cost-saving, with broader age group eligibility yielding even greater benefits.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2634800"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada. 加拿大≥50岁成人使用pneuc -21的成本-效果分析

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-01-14 DOI: 10.1080/14760584.2025.2608811

Peter P Mueller, Marie-Claude Meilleur, Zinan Yi, Amanda Martino, Kwame Owusu-Edusei

{"title":"Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada.","authors":"Peter P Mueller, Marie-Claude Meilleur, Zinan Yi, Amanda Martino, Kwame Owusu-Edusei","doi":"10.1080/14760584.2025.2608811","DOIUrl":"10.1080/14760584.2025.2608811","url":null,"abstract":"Background: This study analyzed the health and economic outcomes of the 21-valent pneumococcal conjugate vaccine (PNEU-C-21; CAPVAXIVE®) compared to either PNEU-C-20 or PNEU-P-23. Cohorts in the cost-effectiveness analyses included vaccine-naïve 57- and 65-year-olds and vaccine-experienced 70-year-olds.Research design and methods: A published Markov model simulated the movement of the Canadian population among four health states: healthy, pneumococcal disease (invasive pneumococcal disease and community-acquired pneumonia attributed to S. pneumoniae), post-meningitis sequelae, and death. The model was populated with published literature and publicly available databases and/or reports. Model inputs included demographic data, epidemiologic data, serotype distribution, vaccine effectiveness, costs, and health-related utilities. The model used a lifetime horizon and 1.5% discounting of costs and life years. Key outcomes included the following: cases, deaths, costs, and incremental cost-effectiveness ratios.Results: The PNEU-C-21 strategy prevented substantially more cases and deaths when compared to the PNEU-C-20 or PNEU-P-23 strategies. For both vaccine-naïve cohorts, the ICERs were dominant for both PNEU-C-21 vs. PNEU-C-20 and PNEU-C-21 vs. PNEU-P-23; among adults aged 70 years, previously vaccinated with PNEU-P-23, PNEU-C-21 was dominant over PNEU-C-20.Conclusions: These results demonstrate that PNEU-C-21 can prevent a substantial number of cases and deaths while remaining highly cost-effective over a range of inputs and scenarios in Canada.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2608811"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance. 预防新生儿败血症的疫苗：重点关注B群链球菌、肺炎克雷伯菌和大肠杆菌，以应对日益严重的抗菌素耐药性。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/14760584.2026.2622690

Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo

{"title":"Vaccines preventing neonatal sepsis: focus on Group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance.","authors":"Francesca Micoli, Simona Rondini, Francesco Berlanda Scorza, Roberto Adamo","doi":"10.1080/14760584.2026.2622690","DOIUrl":"10.1080/14760584.2026.2622690","url":null,"abstract":"Introduction: Neonatal sepsis, a systemic infection occurring in infants within their first 28 days of life, is a leading cause of mortality globally. The burden is especially severe in low- and middle-income countries (LMICs), where incidence and mortality rates are higher than in high-resource settings. Antimicrobial resistance, driven by multidrug-resistant pathogens prevalent in LMICs, further complicates its effective management. Vaccination offers a promising strategy to prevent infections caused by common neonatal sepsis pathogens, potentially reducing sepsis incidence and mitigating resistance.Area covered: This review examines the burden of bacterial pathogens, specifically Group B Streptococcus (GBS), Klebsiella pneumoniae, and Escherichia coli, responsible for neonatal sepsis, drawing from a comprehensive literature search focusing on the last ten years across major databases. It provides an overview of vaccine candidates in clinical development, highlights innovative approaches in preclinical research, and discusses the key challenges associated with vaccine strategies preventing neonatal sepsis.Expert opinion: Given the multivalency of vaccines for neonatal sepsis, innovative technologies are under investigation. Defining correlate of protections has been critical for GBS vaccine development, and may pave the way for vaccines against K. pneumoniae and E. coli. Novel regulatory and clinical strategies, including disease-based rather than pathogen-specific approaches, should be explored.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2622690"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing RSV infection in older adults: implications for public health policy. 处理老年人呼吸道合胞病毒感染：对公共卫生政策的影响

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-15 DOI: 10.1080/14760584.2026.2644348

Floriana D'Ambrosio, Marta Lomazzi, Michael Moore, Roberto Ricciardi, Sabella Mourino, Walter Ricciardi, Giovanna Elisa Calabrò

{"title":"Addressing RSV infection in older adults: implications for public health policy.","authors":"Floriana D'Ambrosio, Marta Lomazzi, Michael Moore, Roberto Ricciardi, Sabella Mourino, Walter Ricciardi, Giovanna Elisa Calabrò","doi":"10.1080/14760584.2026.2644348","DOIUrl":"10.1080/14760584.2026.2644348","url":null,"abstract":"Background: The aging population increases healthcare challenges, especially in preventing infectious diseases. Respiratory syncytial virus (RSV), historically associated with pediatric illness, is now recognized as a significant cause of severe disease and mortality in older adults. Despite scientific advances, including new RSV vaccines, adult immunization policies across Europe remain fragmented and underdeveloped.Research design and methods: This study, promoted by the World Federation of Public Health Associations (WFPHA), assessed RSV surveillance, vaccination strategies, and capacity-building effort in eight European countries (Bulgaria, Finland, Germany, Italy, Norway, Portugal, Spain, and Serbia). A structured questionnaire, informed by a preliminary literature review, was administered to a panel of 19 experts, with a 79% (15/19) response rate.Results: Findings revealed marked heterogeneity and persistent gaps across countries, including fragmented RSV surveillance, limited or missing vaccine recommendations for older adults, lack of age-specific monitoring, and insufficient training and communication initiatives for healthcare providers and the public.Conclusion: To address these issues, the expert panel proposed policy recommendations to improve surveillance, ensure equitable vaccine access, and enhance professional training and awareness, providing a roadmap for stronger, prevention-focused healthcare across Europe.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2644348"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy. 意大利慢性阻塞性肺疾病患者单剂RSVPreF3佐剂疫苗预防呼吸道合胞病毒（RSV）的成本效益

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-16 DOI: 10.1080/14760584.2026.2626916

Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, Giancarlo Lorenzini, Fabiano Di Marco, Giovanna Elisa Calabró

{"title":"Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy.","authors":"Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, Giancarlo Lorenzini, Fabiano Di Marco, Giovanna Elisa Calabró","doi":"10.1080/14760584.2026.2626916","DOIUrl":"10.1080/14760584.2026.2626916","url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) increases the risk of severe respiratory syncytial virus (RSV)-related disease. This analysis evaluated the potential public health impact and cost-effectiveness of RSV vaccination with a single dose of adjuvanted RSVPreF3 vaccine over five years in people aged 60-74 years with COPD in Italy.Research design and methods: A static multi-cohort Markov model estimated RSV-related events, costs, and quality-adjusted life-years (QALY) over five years in people aged 60-74 years with COPD in Italy vaccinated with one dose of adjuvanted RSVPreF3, versus no vaccination. Vaccine efficacy and waning data were based on AReSVi-006 Phase III clinical trial results. Other input data came from published literature and official databases. Sensitivity analyses were conducted.Results: A single dose of adjuvanted RSVPreF3 vaccine (75% coverage) was projected to reduce RSV-related acute respiratory infections by 29% and RSV-related hospitalizations and deaths by 38% among patients with COPD aged 60-74 years in Italy. The incremental cost-effectiveness ratio (health system perspective) was €1,306/QALY.Conclusions: These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626916"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0